Bausch + Lomb and No­valiq win ap­proval for dry eye dis­ease treat­ment

Bausch + Lomb and No­valiq se­cured an ap­proval for their dry eye dis­ease drop on Thurs­day, to be mar­ket­ed as Miebo.

The drug, al­so known as per­flu­o­ro­hexy­loc­tane oph­thalmic so­lu­tion or pre­vi­ous­ly NOV03, tar­gets tear evap­o­ra­tion, a lead­ing cause of dry eye dis­ease. Bausch + Lomb CEO Brent Saun­ders ex­pects the drug to be avail­able in the sec­ond half of this year.

“To­day’s FDA de­ci­sion marks a tremen­dous mile­stone for Bausch + Lomb as MIEBO be­comes our first pre­scrip­tion phar­ma­ceu­ti­cal eye treat­ment to be ap­proved by the FDA since be­com­ing an in­de­pen­dent, pub­licly trad­ed eye health com­pa­ny,” An­drew Stew­art, pres­i­dent of oph­thalmic phar­ma­ceu­ti­cals, said in a news re­lease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER